Making Progress On Novel OTC Switch Rulemaking Has FDA Commissioner Nominee Califf’s Attention
Responding to Sen. Roger Marshall’s question on rulemaking to accelerate OTC switches by allowing NDA sponsors to use extra-label information to guide consumers through self-selection of a drug, Robert Califf said he’d support making progress on a proposal FDA began considering in 2012 in its NSURE initiative.
You may also be interested in...
For first time rules for novel switches and OTC hearings aids are parts of “significant regulatory actions” in agency’s plans. Information is added in Unified Agenda items explaining likely benefits and costs from the changes.
However, the few Senate questions about industry ties, tobacco and food issues may surprise some observers.
Robert Califf got 89 votes in the Senate last time – but that’s also the least a Democratic nominee has ever gotten.